Multi-analyte profile analysis of plasma immune proteins: Altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection

Brain and Behavior

Volumn 4, Issue 2, 2014, Pages 123-142

  Huckans, Marilyn ^a,b   Fuller, Bret E ^a   Olavarria, Hannah ^a   Sasaki, Anna W ^a,b   Chang, Michael ^a,b   Flora, Kenneth D ^c   Kolessar, Michael ^d   Kriz, Daniel ^d   Anderson, Jeanne R ^d   Vandenbark, Arthur A ^a,b   Loftis, Jennifer M ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Oregon Clinic   (United States)

^d PACIFIC UNIVERSITY   (United States)

Author keywords

Anxiety; Biological markers; Chronic infection; Cytokines; Depression; Fatigue; Pain

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA 2 MACROGLOBULIN; ANTIBODY; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CANNABIS; CENTRAL STIMULANT AGENT; COMPLEMENT COMPONENT C3; EOTAXIN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OPIATE; RANTES; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; CYTOKINE; IMMUNOGLOBULIN;

ADULT; ANXIETY; ARTICLE; ASTHMA; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE SEVERITY; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNITY; INTERVIEW; MALE; MENTAL DISEASE; MENTAL FUNCTION; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRIC DISEASE; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUESTIONNAIRE; TOBACCO USE; VIRUS LOAD; BLOOD; CHRONIC HEPATITIS C; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; ANXIETY; BIOMARKERS; CYTOKINES; DEPRESSION; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOPROTEINS; MALE; MIDDLE AGED; PAIN; SEVERITY OF ILLNESS INDEX;

EID: 84896808218     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.200     Document Type: Article

References (131)

1. Abayli, B., A. Canataroglu, and H. Akkiz 2003. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk. J. Gastroenterol. 14:7-11.
2. Akcam, F. Z., A. Tigli, O. Kaya, M. Ciris, and H. Vural 2012. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J. Interferon Cytokine Res. 32:570-574.
3. Alexander, G. M., B. L. Peterlin, M. J. Perreault, J. R. Grothusen, and R. J. Schwartzman 2012. Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome. J. Pain 13:10-20.
4. American Psychiatric Association. 2000. Diagnostic and statistical manual for mental disorders. 4th ed. American Psychiatric Association, Washington, DC.
5. Anderson, G., M. Berk, O. Dean, S. Moylan, and M. Maes 2013. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs. [Epub ahead of print].
6. Argyropoulos, S. V., G. B. Ploubidis, T. S. Wright, M. E. Palm, S. D. Hood, J. R. Nash, et al. 2007. Development and validation of the Generalized Anxiety Disorder Inventory (GADI). J. Psychopharmacol. 21:145-152.
7. Arnett, S. V., and I. A. Clark 2012. Inflammatory fatigue and sickness behaviour-lessons for the diagnosis and management of chronic fatigue syndrome. J. Affect. Disord. 141:130-142.
8. Arnold, S. E., S. X. Xie, Y. Y. Leung, L. S. Wang, M. A. Kling, X. Han, et al. 2012. Plasma biomarkers of depressive symptoms in older adults. Transl. Psychiatry 2:e65.
9. Beck, A. T. 1996. Beck Depression Inventory. 2nd ed. The Psychological Corporation, San Antonio, TX.
10. Breen, E. C., S. M. Reynolds, C. Cox, L. P. Jacobson, L. Magpantay, C. B. Mulder, et al. 2011. Multisite comparison of high-sensitivity multiplex cytokine assays. Clin. Vaccine Immunol. 18:1229-1242.
11. Britschgi, M. and T. Wyss-Coray 2009. Blood protein signature for the early diagnosis of Alzheimer disease. Arch. Neurol. 66:161-165.
12. Bruno, C. M., C. Sciacca, D. Cilio, G. Bertino, A. E. Marchese, G. Politi, et al. 2005. Circulating adhesion molecules in patients with virus-related chronic diseases of the liver. World J. Gastroenterol. 11:4566-4569.
13. Camargo, J. F., P. Quinones, S. Mummidi, S. Srinivas, A. A. Gaitan, K. Begum, et al. 2009. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J. Immunol. 182:171-182.
14. Capuron, L., and A. H. Miller 2011. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 130:226-238.
15. Chen, B., D. Dowlatshahi, G. M. MacQueen, J. F. Wang, and L. T. Young 2001. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50:260-265.
16. Chen, Q. R., Y. K. Song, L. R. Yu, J. S. Wei, J. Y. Chung, S. M. Hewitt, et al. 2010. Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J. Proteome Res. 9:373-382.
17. Cleeland, C. S., and K. M. Ryan 1994. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singapore 23:129-138.
18. ® xMAP technology. Exp. Parasitol. 133:106-113.
19. Corona, A. W., A. M. Fenn, and J. P. Godbout 2012. Cognitive and behavioral consequences of impaired immunoregulation in aging. J. Neuroimmune Pharmacol. 7:7-23.
20. Cortese, G. P., R. M. Barrientos, S. F. Maier, and S. L. Patterson 2011. Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes. J. Neurosci. 31:4274-4279.
21. Dan, A. A., L. M. Martin, C. Crone, J. P. Ong, D. W. Farmer, T. Wise, et al. 2006. Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44:491-498.
22. Dantzer, R. and K. W. Kelley 2007. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 21:153-160.
23. De Masi, R., D. Vergara, S. Pasca, R. Acierno, M. Greco, L. Spagnolo, et al. 2009. PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: a pilot study on relation to clinical findings and brain atrophy. J. Neuroimmunol. 210:80-86.
24. Diniz, B. S., A. L. Teixeira, L. L. Talib, V. A. Mendonca, W. F. Gattaz, and O. V. Forlenza 2010. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J. Psychiatr. Res. 44:917-920.
25. Domenici, E., D. R. Wille, F. Tozzi, I. Prokopenko, S. Miller, A. McKeown, et al. 2010. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 5:e9166.
26. Dowlati, Y., N. Herrmann, W. Swardfager, H. Liu, L. Sham, E. K. Reim, et al. 2010. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67:446-457.
27. Duivis, H. E., N. Vogelzangs, N. Kupper, P. de Jonge, and B. W. Penninx 2013. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 38:1573-1585.
28. Dwight, M. M., K. V. Kowdley, J. E. Russo, P. S. Ciechanowski, A. M. Larson, and W. J. Katon 2000. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J. Psychosom. Res. 49:311-317.
29. Egan, M. F., M. Kojima, J. H. Callicott, T. E. Goldberg, B. S. Kolachana, A. Bertolino, et al. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257-269.
30. El-Gohary, A. M., N. A. Fawaz, H. M. Hassoba, A. Serwah, and M. Ali 2004. Soluble ICAM-1 in patients with chronic hepatitis C infection: a prognostic marker of disease activity. Egypt. J. Immunol. 11:109-119.
31. Falasca, K., C. Ucciferri, M. Dalessandro, P. Zingariello, P. Mancino, C. Petrarca, et al. 2006. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36:144-150.
32. Ferentinos, P., V. Kontaxakis, B. Havaki-Kontaxaki, D. Dikeos, and L. Lykouras 2011. Psychometric evaluation of the Fatigue Severity Scale in patients with major depression. Qual. Life Res. 20:457-465.
33. Fireman, M., D. W. Indest, A. Blackwell, A. J. Whitehead, and P. Hauser 2005. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin. Infect. Dis. 40:S286-S291.
34. Florholmen, J., M. G. Kristiansen, S. E. Steigen, S. W. Sørbye, E. J. Paulssen, J. M. Kvamme, et al. 2011. A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C. Clin. Microbiol. Infect. 17:204-209.
35. Freeman, W. M., A. C. Salzberg, S. W. Gonzales, K. A. Grant, and K. E. Vrana 2010. Classification of alcohol abuse by plasma protein biomarkers. Biol. Psychiatry 68:219-222.
36. Golden, J., A. M. O'Dwyer, and R. M. Conroy 2005. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen. Hosp. Psychiatry 27:431-438.
37. Gomez Ravetti, M. and P. Moscato 2008. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS ONE 3:e3111.
38. Graham, C. S., A. Wells, E. M. Edwards, T. Herren, S. Tumilty, S. O. Stuver, et al. 2007. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J. Infect. Dis. 195:847-856.
39. Gran, B., G. X. Zhang, and A. Rostami 2004. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit. Rev. Immunol. 24:111-128.
40. Grassi-Oliveira, R., E. Brietzke, J. C. Pezzi, R. P. Lopes, A. L. Teixeira, and M. E. Bauer 2009. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin. Neurosci. 63:202-208.
41. Grungreiff, K., T. Hebell, K. Gutensohn, A. Reinhold, and D. Reinhold 2009. Plasma concentrations of zinc, copper, interleukin-6 and interferon-gamma, and plasma dipeptidyl peptidase IV activity in chronic hepatitis C. Mol. Med. Rep. 2:63-68.
42. Hashimoto, K. 2010. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci. 64:341-357.
43. Helaly, G. F., and L. A., Abou Shamaa 2006. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC. Egypt. J. Immunol. 13:27-38.
44. Hestad, K. A., S. Tonseth, C. D. Stoen, T. Ueland, and P. Aukrust 2003. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 19:183-188.
45. Hilsabeck, R. C., G. M. Anstead, A. L. Webb, A. Hoyumpa, P. Ingmundson, S. Holliday, et al. 2010. Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C. J. Neuroimmunol. 221:53-61.
46. Himmerich, H., S. Fulda, J. Linseisen, H. Seiler, G. Wolfram, S. Himmerich, et al. 2008. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 23:421-429.
47. Ho, A. S., C. C. Cheng, S. C. Lee, M. L. Liu, J. Y. Lee, W. M. Wang, et al. 2010. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J. Biomed. Sci. 17:58.
48. Hoge, E. A., K. Brandstetter, S. Moshier, M. H. Pollack, K. K. Wong, and N. M. Simon 2009. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress. Anxiety 26:447-455.
49. Hou, R., and D. S. Baldwin 2012. A neuroimmunological perspective on anxiety disorders. Hum. Psychopharmacol. 27:6-14.
50. Howren, M. B., D. M. Lamkin, and J. Suls 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71:171-186.
51. Hu, W. T., A. Chen-Plotkin, S. E. Arnold, M. Grossman, C. M. Clark, L. M. Shaw, et al. 2010. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 119:669-678.
52. Jones, K. A., and C. Thomsen 2013. The role of the innate immune system in psychiatric disorders. Mol. Cell. Neurosci. 53:52-62.
53. Keller, S., C. M. Bann, S. L. Dodd, J. Schein, T. R. Mendoza, and C. S. Cleeland 2004. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin. J. Pain 20:309-318.
54. Kikly, K., L. Liu, S. Na, and J. D. Sedgwick 2006. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 18:670-675.
55. Kleinman, L., M. W. Zodet, Z. Hakim, J. Aledort, C. Barker, K. Chan, et al. 2000. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual. Life Res. 9:499-508.
56. Krügel, U., J. Fischer, S. Radicke, U. Sack, and H. Himmerich 2013. Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res. 47:611-616.
57. Krupp, L. B., N. G. LaRocca, J. Muir-Nash, and A. D. Steinberg 1989. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46:1121-1123.
58. Kubera, M., A. H. Lin, G. Kenis, E. Bosmans, D. van Bockstaele, and M. Maes 2001. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J. Clin. Psychopharmacol. 21:199-206.
59. Kurita, M., S. Nishino, M. Kato, Y. Numata, and T. Sato 2012. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS ONE 7:e39212.
60. Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, et al. 2006. IL-23 promotes tumour incidence and growth. Nature 442:461-465.
61. Lapiński, T. W., A. Kot, and D. Prokopowicz 2002. Concentration of b2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-a therapy. Med. Sci. Monit. 8:CR538-CR542.
62. Larrubia, J. R., S. Benito-Martínez, M. Calvino, E. Sanz-de-Villalobos, and T. Parra-Cid 2008. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J. Gastroenterol. 14:7149-7159.
63. Lavanchy, D. 2009. The global burden of hepatitis C. Liver Int. 29:74-81.
64. Lee, N. P., L. Chen, M. C. Lin, F. H. Tsang, C. Yeung, R. T. Poon, et al. 2009. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J. Proteome Res. 8:1293-1303.
65. Leonard, B., and M. Maes 2012. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 36:764-785.
66. Leroy, V., F. Monier, S. Bottari, C. Trocme, N. Sturm, M. N. Hilleret, et al. 2004. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 99:271-279.
67. Levine, J., Y. Barak, K. N. Chengappa, A. Rapoport, M. Rebey, and V. Barak 1999. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40:171-176.
68. Loftis, J. M., and P. Hauser 2004. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 82:175-190.
69. Loftis, J. M., M. Huckans, S. Ruimy, D. J. Hinrichs, and P. Hauser 2008. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci. Lett. 430:264-268.
70. Loftis, J. M., M. Huckans, and B. J. Morasco 2010. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol. Dis. 37:519-533.
71. Loftis, J. M., A. L. Patterson, C. J. Wilhelm, H. McNett, B. J. Morasco, M. Huckans, et al. 2013a. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J. Psychosom. Res. 74:57-63.
72. Loftis, J. M., C. J. Wilhelm, A. A. Vandenbark, and M. Huckans 2013b. Partial MHC/neuropeptide: a potential neuroimmune-based treatment for methamphetamine addiction. PLoS ONE 8:e56306.
73. Lotrich, F. E., S. Albusaysi, and R. E. Ferrell 2012. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment. Neuropharmacology 38:985-995.
74. Maes, M., H. Y. Meltzer, E. Bosmans, R. Bergmans, E. Vandoolaeghe, R. Ranjan, et al. 1995. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34:301-309.
75. Maes, M., C. Song, A. H. Lin, S. Bonaccorso, G. Kenis, R. De Jongh, et al. 1999. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20:370-379.
76. Maes, M., R. Yirmyia, J. Noraberg, S. Brene, J. Hibbeln, G. Perini, et al. 2009. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24:27-53.
77. Maes, M., B. Leonard, A. Fernandez, M. Kubera, G. Nowak, R. Veerhuis, et al. 2011. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:659-663.
78. Malaguarnera, M., I. Di Fazio, L. Ferlito, G. Pistone, A. Laurino, E. Vinci, et al. 2000. Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 12:937-939.
79. Marksteiner, J., G. Kemmler, E. M. Weiss, G. Knaus, C. Ullrich, S. Mechtcheriakov, et al. 2011. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 32:539-540.
80. Martin-Santos, R., C. Diez-Quevedo, P. Castellvi, R. Navines, M. Miquel, H. Masnou, et al. 2008. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment. Pharmacol. Ther. 27:257-265.
81. McAfoose, J., and B. T. Baune 2009. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 33:355-366.
82. Meyers, C. A., M. Albitar, and E. Estey 2005. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788-793.
83. Miller, A. H., E. Haroon, C. L. Raison, and J. C. Felger 2013. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety 30:297-306.
84. Mommersteeg, P. M., E. Vermetten, A. Kavelaars, E. Geuze, and C. J. Heijnen 2008. Hostility is related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology 33:1041-1050.
85. Muller, N., M. J. Schwarz, S. Dehning, A. Douhe, A. Cerovecki, B. Goldstein-Muller, et al. 2006. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11:680-684.
86. Nelligan, J. A., J. M. Loftis, A. M. Matthews, B. L. Zucker, A. M. Linke, and P. Hauser 2008. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. J. Clin. Psychiatry 69:810-816.
87. O'Brien, S. M., P. Scully, P. Fitzgerald, L. V. Scott, and T. G. Dinan 2007. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41:326-331.
88. O'Bryant, S. E., S. C. Waring, V. Hobson, J. R. Hall, C. B. Moore, T. Bottiglieri, et al. 2010. Decreased C-reactive protein levels in Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23:49-53.
89. Owen, B. M., D. Eccleston, I. N. Ferrier, and A. H. Young 2001. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr. Scand. 103:226-228.
90. Patel, A., A. Siegel, and S. S. Zalcman 2010. Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav. Immun. 24:1276-1280.
91. Patterson, A. L., B. J. Morasco, B. E. Fuller, D. W. Indest, J. M. Loftis, and P. Hauser 2011. Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity? Gen. Hosp. Psychiatry 33:354-362.
92. Pawlak, K., M. Mysliwiec, and D. Pawlak 2010. Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas-the new putative determinants of endothelial dysfunction in haemodialysis patients. Thromb. Res. 126:393-398.
93. Potter, A., L. Downey, and C. Stough 2013. Cognitive function in ecstasy naive abstinent drug dependants and MDMA users. Curr. Drug Abuse Rev. 6:71-76.
94. Poynard, T., P. Cacoub, V. Ratziu, R. P. Myers, M. H. Dezailles, A. Mercadier, et al. 2002. Fatigue in patients with chronic hepatitis C. J. Viral Hepat. 9:295-303.
95. Raison, C. L., R. E. Rutherford, B. J. Woolwine, C. Shuo, P. Schettler, D. F. Drake, et al. 2013. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31-41.
96. Rethorst, C. D., M. S. Toups, T. L. Greer, P. A. Nakonezny, T. J. Carmody, B. D. Grannemann, et al. 2013. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry 18:1119-1124.
97. Rowan, P. J., R. Al-Jurdi, S. Tavakoli-Tabasi, M. E. Kunik, S. L. Satrom, and H. B. El-Serag 2005. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J. Clin. Gastroenterol. 39:731-736.
98. Salim, S., G. Chugh, and M. Asghar 2012. Inflammation in anxiety. Adv. Protein Chem. Struct. Biol. 88:1-25.
99. Schafers, M., C. Sommer, C. Geis, T. Hagenacker, P. Vandenabeele, and L. S. Sorkin 2008. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience 157:414-423.
100. Schall, T. J. and K. B. Bacon 1994. Chemokines, leukocyte trafficking, and inflammation. Curr. Opin. Immunol. 6:865-873.
101. Schmidt, H. D., R. C. Shelton, and R. S. Duman 2011. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36:2375-2394.
102. Schrijvers, E. M., P. J. Koudstaal, A. Hofman, and M. M. Breteler 2011. Plasma clusterin and the risk of Alzheimer disease. JAMA 305:1322-1326.
103. Sekine, Y., Y. Ouchi, G. Sugihara, N. Takei, E. Yoshikawa, K. Nakamura, et al. 2008. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28:5756-5761.
104. Sen, S., R. Duman, and G. Sanacora 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64:527-532.
105. Sharma, A., A. Chakraborti, A. Das, R. K. Dhiman, and Y. Chawla 2009. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 128:e514-e522.
106. Sheehan, D. V., Y. Lecrubier, K. H. Sheehan, P. Amorim, J. Janavs, E. Weiller, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:22-33.
107. Simen, B. B., C. H. Duman, A. A. Simen, and R. S. Duman 2006. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol. Psychiatry 59:775-785.
108. Simon, N. M., K. McNamara, C. W. Chow, R. S. Maser, G. I. Papakostas, M. H. Pollack, et al. 2008. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur. Neuropsychopharmacol. 18:230-233.
109. Slade, G. D., M. S. Conrad, L. Diatchenko, N. U. Rashid, S. Zhong, S. Smith, et al. 2011. Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. Pain 152:2802-2812.
110. Sluzewska, A., J. K. Rybakowski, M. Laciak, A. Mackiewicz, M. Sobieska, and K. Wiktorowicz 1995. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 762:474-476.
111. Sousa, G. M., I. S. Oliveira, L. J. Andrade, M. L. Sousa-Atta, R. Paraná, and A. M. Atta 2012. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine 60:138-142.
112. Tan, G., M. P. Jensen, J. I. Thornby, and B. F. Shanti 2004. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J. Pain 5:133-137.
113. Tawadrous, G. A., A. A. Aziz, D. G. Amin, A. Eldemery, and M. A. Mostafa 2012. RANTES, TNF-alpha, oxidative stress, and hematological abnormalities in hepatitis C virus infection. J. Investig. Med. 60:878-882.
114. Tong, L., R. Balazs, R. Soiampornkul, W. Thangnipon, and C. W. Cotman 2008. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol. Aging 29:1380-1393.
115. Toro-Nieves, D. M., Y. Rodriguez, M. Plaud, P. Ciborowski, F. Duan, J. Perez Laspiur, et al. 2009. Proteomic analyses of monocyte-derived macrophages infected with human immunodeficiency virus type 1 primary isolates from Hispanic women with and without cognitive impairment. J. Neurovirol. 15:36-50.
116. Tyring, S., A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, A. Wang, et al. 2006. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29-35.
117. Udina, M., P. Castellví, J. Moreno-España, R. Navinés, M. Valdés, X. Forns, et al. 2012. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 73:1128-1138.
118. Vecchiet, J., K. Falasca, P. Cacciatore, P. Zingariello, M. Dalessandro, M. Marinopiccoli, et al. 2005. Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann. Clin. Lab. Sci. 35:415-422.
119. Vignali, D. A. 2000. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 243:243-255.
120. Vogel, C., S. Stallforth, and C. Sommer 2006. Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J. Peripher. Nerv. Syst. 11:294-303.
121. Vom Berg, J., S. Prokop, K. R. Miller, J. Obst, R. E. Kälin, I. Lopategui-Cabezas, et al. 2012. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18:1812-1819.
122. Wang, G. J., N. D. Volkow, L. Chang, E. Miller, M. Sedler, R. Hitzemann, et al. 2004. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry 161:242-248.
123. Warshow, U. M., A. Riva, D. Hegazy, P. H. Thurairajah, E. R. Kaminski, S. Chokshi, et al. 2012. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. J. Viral Hepat. 19:501-508.
124. Wechsler, D. 2001. Wechsler Test of Adult Reading (WTAR). Pearson, San Antonio, TX.
125. Whitehead, A. J., S. K. Dobscha, B. J. Morasco, S. Ruimy, C. Bussell, and P. Hauser 2008. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C. J. Pain Symptom Manage. 36:39-45.
126. Wichers, M. C., G. Kenis, C. Leue, G. Koek, G. Robaeys, and M. Maes 2006. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol. Psychiatry 60:77-79.
127. Wilhelm, C. J., D. Choi, M. Huckans, L. Manthe, and J. M. Loftis 2013. Adipocytokine signaling is altered in Flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression. Pharmacol. Biochem. Behav. 103:643-651.
128. Wilkinson, J., M. Radkowski, J. M. Eschbacher, and T. Laskus 2010. Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 59:1394-1400.
129. Yaffe, K., A. Kanaya, K. Lindquist, E. M. Simonsick, T. Harris, R. I. Shorr, et al. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292:2237-2242.
130. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310-1316.
131. Zimmermann, H. W., S. Seidler, N. Gassler, J. Nattermann, T. Luedde, C. Trautwein, et al. 2011. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS ONE 6:e21381.